John Klein - Guiding Cambridge Therapeutics in New Jersey

The chairman of Alpine, New Jersey-based Cambridge Therapeutics, John Klein offers next-generation solutions in areas ranging from combination therapies to drug delivery. Building on his experience with Cambridge Therapeutics, John Klein recently launched Bilogix in Alpine, NJ, a provider of enterprise performance management (EPM) consulting services. Encompassing processes and applications, the EPM approach is one that transforms key performance indicator (KPI) data into highly accurate ways of analyzing, monitoring, measuring, and forecasting organizational results. It adds value through bringing focus on the details of how strategic plans are envisioned and implemented, as well as how challenges and inconsistencies are addressed when they occur. This ensures that resources are utilized more efficiently toward defined goals, at both the operational and tactical levels. At the same time, the effects of business intelligence investments can be tracked via a dashboard and r...

Technavio logo image: technavio.com A former Mitchell & Co. Outstanding CEO honoree, John Klein serves as chairman of Cambridge Therapeutics, which he founded in 2011 to deliver combination drug therapies. Concurrently, John Klein is the chairman and CEO of the Alpine, NJ-based Bilogix, LLC, through which he provides enterprise performance management (EPM) solutions to business clients to better inform their decision-making processes and improve operational performance. According to Technavio , the EPM application market is expected to grow by more than $2 billion by 2023, which equates to a compound annual growth rate of nearly 9 percent. Technavio has been monitoring the global market since 2015 and presented its findings in its recent 132-page market analysis report. The report states that market growth will be driven by demand for cloud-based EPM solutions in addition to companies seeking to satisfy changing regulations. Given the volume and sensitive nature of data trans...

The chairman of Cambridge Therapeutics in Teaneck, New Jersey, John Klein has obtained FDA approval for more than 300 generic drugs in the course of his 30-year career. His work at Cambridge Therapeutics has resulted in honors including high ranking on Forbes’ list of the Top 100 CEOs. Complementing that work, John Klein closely follows health and related developments in New Jersey. The state’s attorney general, Gurbir Grewal, recently announced new efforts aimed at battling the state’s opioid epidemic. Grewal has proposed a rule change to make medication-assisted treatment, long recognized as the most effective way to treat opioid addiction, more widely available to the state’s residents through use of telemedicine technology. Allowing physicians to assess and prescribe treatments to patients through two-way, real-time video communication will ensure more people can access medication-assisted treatment and improve their odds of surviving their opioid addiction. In addition, Grewa...

John Klein has led Teaneck, New Jersey-based Cambridge Therapeutics since founding the pharmaceutical products manufacturer nearly a decade ago. He and his company provide a range of customer-friendly medical packaging options designed to increase patient adherence to prescription regimens. In addition to his role with Cambridge Therapeutics, John Klein is a board member with Hackensack Meridian Health Hospitals and regularly studies emerging information in the healthcare field in his state. In order to care for the most vulnerable of its citizens, the state of New Jersey oversees NJFamilyCare , a publicly funded insurance program that offers free or affordable health insurance for individuals of all ages. The program entitles policy holders to obtain visits to physicians, dentists, mental health professionals, and vision care specialists, as well as hospital services. However, the research group New Jersey Policy Perspective noted that the number of children enrolled in NJFamilyCar...

Cambridge Therapeutics leader John Klein has been in the pharmaceutical industry for nearly 30 years. In addition to his professional commitments to healthcare, John Klein is interested in improving education in his home state of New Jersey, where he serves as a trustee of the private preparatory school Dwight-Englewood, also known as D-E. The Dwight-Englewood School teaches children from kindergarten through high school in an innovative setting that emphasizes academic excellence. Recently, the community website Niche.com ranked D-E third among the top 100 private and public schools at all grade levels in the state and second among state private schools only. It earned a grade rating of A+. Factors considered for the evaluation of New Jersey’s schools included not only academics, but also the racial and economic diversity of the student population, parent and student experiences, and teacher performance, along with a collection of smaller factors. Dwight-Englewood’s ranking in this...